Clinical trial
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic…
NCT00104897 · Cancer Research UK, Other · Completed
Key facts
| NCT number | NCT00104897 |
|---|---|
| Title | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma |
| Official title | A Phase II Trial to Assess the Activity of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) in Patients With Metastatic (M1, M1b & M1c) Malignant Melanoma |
| Lead sponsor | Cancer Research UK, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | tanespimycin |
| Enrollment | 25 |
| Start date | Mar 1, 2005 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Mar 4, 2005 |
| Last update posted | Jun 26, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: